Logo image of VRCA

VERRICA PHARMACEUTICALS INC (VRCA) Stock Price, Quote, News and Overview

NASDAQ:VRCA - Nasdaq - US92511W1080 - Common Stock - Currency: USD

0.469  0 (-0.28%)

After market: 0.4922 +0.02 (+4.95%)

VRCA Quote, Performance and Key Statistics

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (5/2/2025, 8:28:02 PM)

After market: 0.4922 +0.02 (+4.95%)

0.469

0 (-0.28%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High11.41
52 Week Low0.38
Market Cap43.36M
Shares92.46M
Float48.78M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07
IPO06-15 2018-06-15


VRCA short term performance overview.The bars show the price performance of VRCA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

VRCA long term performance overview.The bars show the price performance of VRCA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of VRCA is 0.469 USD. In the past month the price increased by 11.67%. In the past year, price decreased by -93.54%.

VERRICA PHARMACEUTICALS INC / VRCA Daily stock chart

VRCA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 59.86 780.78B
JNJ JOHNSON & JOHNSON 15.53 375.64B
NVO NOVO-NORDISK A/S-SPONS ADR 20.01 307.32B
NVS NOVARTIS AG-SPONSORED ADR 13.75 225.73B
AZN ASTRAZENECA PLC-SPONS ADR 19.47 224.59B
MRK MERCK & CO. INC. 10.68 209.31B
PFE PFIZER INC 7.54 137.25B
SNY SANOFI-ADR 14.36 135.72B
BMY BRISTOL-MYERS SQUIBB CO 6.89 102.91B
GSK GSK PLC-SPON ADR 7.09 79.05B
ZTS ZOETIS INC 26.59 70.23B
HLN HALEON PLC-ADR 21.84 48.25B

About VRCA

Company Profile

VRCA logo image Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Company Info

VERRICA PHARMACEUTICALS INC

10 N High St Ste 200

West Chester PENNSYLVANIA 19380 US

CEO: Ted White

Employees: 71

VRCA Company Website

VRCA Investor Relations

Phone: 14844533300

VERRICA PHARMACEUTICALS INC / VRCA FAQ

What is the stock price of VERRICA PHARMACEUTICALS INC today?

The current stock price of VRCA is 0.469 USD. The price decreased by -0.28% in the last trading session.


What is the ticker symbol for VERRICA PHARMACEUTICALS INC stock?

The exchange symbol of VERRICA PHARMACEUTICALS INC is VRCA and it is listed on the Nasdaq exchange.


On which exchange is VRCA stock listed?

VRCA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VERRICA PHARMACEUTICALS INC stock?

12 analysts have analysed VRCA and the average price target is 3.4 USD. This implies a price increase of 624.94% is expected in the next year compared to the current price of 0.469. Check the VERRICA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VERRICA PHARMACEUTICALS INC worth?

VERRICA PHARMACEUTICALS INC (VRCA) has a market capitalization of 43.36M USD. This makes VRCA a Nano Cap stock.


How many employees does VERRICA PHARMACEUTICALS INC have?

VERRICA PHARMACEUTICALS INC (VRCA) currently has 71 employees.


What are the support and resistance levels for VERRICA PHARMACEUTICALS INC (VRCA) stock?

VERRICA PHARMACEUTICALS INC (VRCA) has a resistance level at 0.48. Check the full technical report for a detailed analysis of VRCA support and resistance levels.


Is VERRICA PHARMACEUTICALS INC (VRCA) expected to grow?

The Revenue of VERRICA PHARMACEUTICALS INC (VRCA) is expected to grow by 104.5% in the next year. Check the estimates tab for more information on the VRCA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VERRICA PHARMACEUTICALS INC (VRCA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VERRICA PHARMACEUTICALS INC (VRCA) stock pay dividends?

VRCA does not pay a dividend.


When does VERRICA PHARMACEUTICALS INC (VRCA) report earnings?

VERRICA PHARMACEUTICALS INC (VRCA) will report earnings on 2025-05-07.


What is the Price/Earnings (PE) ratio of VERRICA PHARMACEUTICALS INC (VRCA)?

VERRICA PHARMACEUTICALS INC (VRCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).


What is the Short Interest ratio of VERRICA PHARMACEUTICALS INC (VRCA) stock?

The outstanding short interest for VERRICA PHARMACEUTICALS INC (VRCA) is 5.83% of its float. Check the ownership tab for more information on the VRCA short interest.


VRCA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to VRCA. When comparing the yearly performance of all stocks, VRCA is a bad performer in the overall market: 96.53% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VRCA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to VRCA. VRCA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VRCA Financial Highlights

Over the last trailing twelve months VRCA reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -5.48% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -141.46%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%54.72%
Sales Q2Q%-82.7%
EPS 1Y (TTM)-5.48%
Revenue 1Y (TTM)47.54%

VRCA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 77% to VRCA. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 79.96% and a revenue growth 104.5% for VRCA


Ownership
Inst Owners29.48%
Ins Owners37.53%
Short Float %5.83%
Short Ratio6.31
Analysts
Analysts76.67
Price Target3.4 (624.95%)
EPS Next Y79.96%
Revenue Next Year104.5%